Consumption of Caffeinated Beverages and Kidney Function Decline in an Elderly Mediterranean Population with Metabolic Syndrome by Díaz López, Andrés et al.
1
Vol.:(0123456789)
Scientific Reports |         (2021) 11:8719  | https://doi.org/10.1038/s41598-021-88028-7
www.nature.com/scientificreports
Consumption of caffeinated 
beverages and kidney function 
decline in an elderly Mediterranean 
population with metabolic 
syndrome
Andrés Díaz‑López1,2,3,4, Indira Paz‑Graniel2,3,4, Verónica Ruiz2,5, Estefanía Toledo4,6, 
Nerea Becerra‑Tomás2,3,4,7*, Dolores Corella4,7, Olga Castañer4,8, J. Alfredo Martínez4,9,10, 
Ángel M. Alonso‑Gómez4,11, Julia Wärnberg4,12, Jesús Vioque13,14, Dora Romaguera4,15, 
José López‑Miranda4,16, Ramon Estruch4,17, Francisco J. Tinahones4,18, 
José Lapetra4,19, Luís Serra‑Majem4,20, Aurora Bueno‑Cavanillas14,21, Josep A. Tur4,15,22, 
Vicente Martín Sánchez14,23, Xavier Pintó4,24, Miguel Delgado‑Rodríguez14,25, 
Pilar Matía‑Martín26, Josep Vidal27,28, Clotilde Vázquez4,29, Lidia Daimiel10, 
Tania Fernandez Villa14,23, Emilio Ros4,30, Sonia Eguaras4,6, Nancy Babio2,3,4, Jose V. Sorlí4,7, 
Albert Goday4,8, Itziar Abete4,9, Lucas Tojal Sierra4,11, Francisco Javier Barón‑López31, 
Laura Torres‑Collado13, Marga Morey4,15, Antonio Garcia‑Rios4,16, Rosa Casas4,17, 
María Rosa Bernal‑López4,18, José Manuel Santos‑Lozano4,19, Adela Navarro4,6, 
Jose I. Gonzalez4,7, María Dolores Zomeño4,8, Maria Angeles Zulet4,9, 
Jessica Vaquero Luna4,12, Raul Ramallal4,6, Montse Fitó4,8 & Jordi Salas‑Salvadó2,3,4,5,32*
It remains unclear whether caffeinated beverages could have deleterious renal effects in elderly 
population with underlying comorbid conditions. We investigated the associations between coffee, 
tea, or caffeine intake and 1‑year changes in glomerular filtration rate (eGFR) in a large Spanish cohort 
of overweight/obese elderly with metabolic syndrome (MetS). This prospective analysis includes 5851 
overweight/obese adults (55–75 years) with MetS from the PREDIMED‑Plus study. We assessed coffee, 
tea, and caffeine consumption from a validated food‑frequency questionnaire and creatinine‑based 
eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation. Multivariate‑adjusted 
regression models were applied to test associations between baseline coffee, tea, or caffeine intake 
and 1‑year eGFR changes. Caffeinated coffee (> 2 cups/day) and tea (at least 1 cup/day) drinkers had 
0.88 and 0.93 mL/min/1.73  m2 greater eGFR decrease respectively, compared to those with less than 
1 cup/day of coffee consumption or non‑tea drinkers. Furthermore, caffeinated coffee consumption 
of > 2 cups/day was associated with 1.19‑fold increased risk of rapid eGFR decline > 3 mL/min/1.73  m2 
(95% CI 1.01–1.41). Similarly, individuals in the highest (median, 51.2 mg/day) tertile of caffeine intake 
had a 0.87 mL/min/1.73  m2 greater eGFR decrease. Decaffeinated coffee was not associated with eGFR 
changes. In conclusion, higher consumption of caffeinated coffee, tea, and caffeine was associated 
with a greater 1‑year eGFR decline in overweight/obese adults with MetS.
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Abbreviations
ARBs  Angiotensin-type 2 receptor blockers
ACEis  Angiotensin converting enzyme inhibitors
CKD  Chronic Kidney Disease
CKD-EPI  Chronic Kidney Disease Epidemiology Collaboration
CIs  Confidence intervals
DBP  Diastolic blood pressure
eGFR  Estimated glomerular filtration rate
HDL-c  High-density lipoprotein-cholesterol
MedDiet  Mediterranean diet
MetS  Metabolic syndrome
BMI  Body mass index
PREDIMED  PREvención con DIeta MEDiterranea
SFFQ  Semiquantitative food-frequency questionnaire
SBP  Systolic blood pressure
Chronic kidney disease (CKD) poses a major public health challenge due to its detrimental impact on quality 
of life, increased morbidity and premature death, specifically in old  people1. This heterogeneous condition is 
characterized by a decline of glomerular filtration rate (eGFR) and/or  proteinuria2, which is accelerated when 
obesity or related cardiovascular risk factors are  present3. Therefore, preserving renal function is essential to 
ensure the well-being and reduce adverse health outcomes in elders.
Many dietary components play a role in preserving renal function and preventing/delaying CKD 
 progression4,5, such as coffee and  tea6,7, two caffeine-containing beverages that are widely consumed worldwide. 
Coffee and tea are rich in bioactive substances, such as phenolic compounds and minerals with antioxidant and 
anti-inflammatory properties, which can improve blood pressure, oxidative stress, dyslipidemia, and insulin 
resistance or  hyperglycemia8,9, well-established risk factors for renal insufficiency. There is evidence pointing to a 
protective effect of coffee and tea against type 2 diabetes, hypertension, and cardiovascular disease, conditions in 
which chronic inflammation plays a critical pathogenic  role10–12. Nonetheless, there are potential side effects from 
caffeine contained in these beverages, even at moderate amounts, which may influence CKD-related cardiovascu-
lar outcomes and are of concern for the general population and especially for susceptible or at-risk  individuals13.
The results of epidemiological studies on coffee and tea consumption and kidney function have been 
 inconsistent14–23. Two recent meta-analyses, summarizing 7 cross-sectional studies on apparently healthy middle-
aged adults, most from Asian countries, have concluded that coffee consumption is not associated with eGFR 
or CKD  risk6,7. Regarding prospective studies; some studies reported a lower incidence of  CKD21,24 or end-stage 
renal  disease19 with greater coffee consumption, while others failed to demonstrate this  association22. For tea 
consumption, the few studies examining its association with eGFR or CKD risk reported null  findings15,19,20,22. 
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Several limitations of these studies need to be addressed; (1) most previous studies are cross-sectional rather than 
longitudinal studies, (2) they only reported information on total coffee consumption and not its subtypes (caf-
feinated and decaffeinated coffee), (3) stratified analyses were often not reported, and (4) they were performed in 
general healthy adults, and not in vulnerable elderly individuals. In addition, the impact of coffee or tea on eGFR 
could be different among countries with different lifestyle and tea and coffee-drinking habits. Consequently, it 
is unclear whether caffeinated beverages have deleterious effects on kidney function in elderly population with 
underlying comorbid conditions. Therefore, the purpose of this study was to address the associations of caf-
feinated and decaffeinated coffee, tea, and caffeine consumption with 1-year changes in eGFR in a large Spanish 
cohort of overweight/obese older individuals with metabolic syndrome (MetS).
Methods
Study design and participants. The present data was analysed using an observational prospective design 
conducted within the frame of the PREDIMED-PLUS study, which included 6874 older adults enrolled between 
2013 and 2016 by 23 Spanish centers working in collaboration with 208 National Health System primary care 
clinics. Briefly, PREDIMED-Plus is an ongoing, 6-year, multicenter, parallel randomized clinical trial (RCT) 
evaluating the long-term effect of a weight-loss intervention based on an energy-reduced Mediterranean diet 
(MedDiet), physical activity promotion and behavioral support (intervention), in comparison with usual-care 
recommending an energy-unreduced MedDiet (control), on primary cardiovascular prevention. Eligible partici-
pants were overweight/obese (BMI 27–40 kg/m2) men and women aged 55–75 years harboring the  MetS25, but 
free of cardiovascular disease at enrollment. More specific details of the study cohort and inclusion/exclusion 
criteria have been  reported26,27 and the protocol is available at http:// predi medpl us. com/. Local Ethics Commit-
tee approved the study protocol and all participants signed a written informed consent.
For the current study, participants who did not complete the semiquantitative food-frequency questionnaire 
(SFFQ) at baseline (n = 53) or those whose total energy intake was outside pre-defined limits (women < 500 
and > 3500 kcal/day, and men < 800 and > 4000 kcal/day) (n = 188) were excluded. We also excluded subjects who 
died (n = 11) or were lost to follow-up (n = 16) within first year of follow-up, and who had missing data on eGFR 
at baseline or at the 1-year assessment. The remaining 5851 participants comprised the final sample.
Assessment of coffee, tea, and caffeine. The exposures of interest were baseline consumption of coffee 
(caffeinated and decaffeinated coffee), tea, and total caffeine intake. Trained dietitians collected participant infor-
mation about dietary intake through face-to-face interviews using a Spanish version of the validated 143-item 
 SFFQ28. Participants reported their average frequency of consumption over the preceding year for a specified serv-
ing size of each item. The nine possible answers ranged from “never or less than once per month” to “six or more 
per day”, which were transformed into grams or milliliters per day using the standard portion size of each food and 
beverage. Two and one items on the FFQ were specifically related to coffee consumption (one for caffeinated coffee 
and one for decaffeinated coffee) and tea consumption, respectively. The standard serving size of 1 cup of coffee or 
tea was assigned as 50 mL in the questionnaire. Total coffee consumption was considered as the sum of caffeinated 
and decaffeinated coffee. Spanish food composition tables were used to estimate daily energy and nutrient  intakes29.
We modeled three categories of coffee consumption (0 to < 1cup/day, 1–2 cups/day, and > 2 cups/day) and 
tea consumption (0 cup/day, < 1 cup/day, and ≥ 1 cups/day) with the lowest category as the referent group. Total 
caffeine intake was computed from the SFFQ using the caffeine contained in caffeinated coffee (400 mg/L), decaf-
feinated coffee (10.7 mg/L), tea (100 mg/L), regular sodas (79.2 mg/L), artificially sweetened soda (128 mg/L) 
and chocolate (180 mg/kg). Reference values from the European Food Safety  Authority30 were used to calculate 
caffeine intake. For data analyses, caffeine intake (mg/day) was categorized into tertiles. We did not collect any 
information on the types of tea, soda, and chocolate.
Assessment of the outcome and covariates. The main outcome of interest for the present study was 
1-year changes in kidney function, assessed by changes in eGFR (1-year data minus baseline data) estimated 
indirectly from serum creatinine (SCr) using the Chronic Kidney Disease Epidemiology Collaboration equation 
for Caucasian  individuals31. SCr levels were determined by the enzymatic creatinine assay method (coefficient 
of variation < 4.0%). The secondary outcome was a rapid decline of kidney function, defined as 1-year eGFR 
decline rate > 3 mL/min/1.73  m2. This threshold represents a magnitude of change that is 3 times the decline rate 
imposed by natural ageing.
At baseline, trained staff collected participant’s information through questionnaires regarding sociode-
mographic characteristics (sex, age, education, and employment status), lifestyles factors (smoking, physical 
 activity32,33), history of illnesses and medication use. Additionally, we assessed adherence to the MedDiet using 
a 17-item questionnaire, adapted from a previously validated  questionnaire34. This tool was used to evaluate 
compliance with the intervention and as a key element to guide the motivational interviews during the follow-
up. Compliance with each of the 17 items relating to characteristic food habits was scored with 1 or 0 points, 
when the criterion was met or not met, respectively. Therefore, the total MedDiet score range was 0–17, with 0 
meaning no adherence and 17 meaning maximum adherence to MedDiet. Weight, height and waist circumfer-
ence were determined in duplicate by trained personnel following a pre-established protocol. BMI was calculated 
by dividing the weight (kg) by the height squared  (m2). Blood pressure was measured at rest in triplicate by an 
automated digital device (Omron-HEM297705C). At baseline and 1-year, blood samples were collected after an 
overnight fast, and routine biochemical analyses including fasting glucose, lipid profile, and SCr was performed.
Statistical analyses. All analyses were performed by STATA software, v.15.0 (StataCorp LP, Tx. USA) 
using the PREDIMED-Plus database updated in March 2019.
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Descriptive data are presented as mean ± SD for quantitative variables or percentages for qualitative vari-
ables. Baseline characteristics of the study population across categories of total coffee and tea consumption were 
compared using ANOVA and chi-square tests, as appropriate.
Multivariate linear regression models were applied to test associations between categories (lowest category 
as reference) of coffee, tea, and caffeine intake and changes in eGFR at 1 year. For these associations, coffee, tea, 
(both for each cup/day increase) and caffeine (for each 50 mg/day increase) were also analyzed as continuous 
variables. The results are presented as β-coefficients and 95% confidence intervals (CIs). Furthermore, ORs were 
calculated for the association between categories of coffee and tea consumption and rapid eGFR decline (1-year 
changes in eGFR > 3 mL/min/1.73  m2). Three models with additional adjustment for potential confounders were 
fitted: model 1, adjusted for sex (men/women), age (years, continuous), and baseline eGFR (mL/min/1.73  m2, 
continuous); model 2, additionally adjusted for BMI (kg/m2, continuous), smoking (never, current or former 
smoker), education (primary, secondary education or academic/graduate), physical activity (MET-min/day, 
continuous), type 2 diabetes (yes/no), dyslipidemia (yes/no), hypertension (yes/no), center (four categories by 
number of recruited participants: < 200, 200–250, 250–300, or ≥ 300), treatment group (intervention/control), 
MedDiet score (17-points, continuous), and total energy intake (kcal/day, quartiles); to minimize confounding 
by other dietary factors, a third model (model 3) was additionally adjusted for dietary intakes of total protein, 
saturated fat, alcohol, fiber, sodium, magnesium, potassium (each categorized at energy-adjusted quartiles by 
using the residual  method35), 1-year changes in systolic blood pressure (mmHg, continuous), and 1-year changes 
body weight (kg, continuous). Model 3 was further adjusted (cup/day, continuous) for coffee (for tea), tea (for 
each coffee), caffeinated coffee (for decaffeinated coffee), or decaffeinated coffee (for caffeinated coffee). All 
models were conducted with robust variance estimators to account for intra-cluster correlations, considering 
as clusters the members of the same household (n = 354 couples). Tests for linear trends across categories were 
conducted by modeling the median value for coffee, tea, or caffeine intake categories as continuous variables.
Furthermore, stratified analyses were conducted by intervention group (intervention/control), sex, age 
(≤ 65/ > 65 years), baseline eGFR (≥ 90 mL/min/1.73  m2, 60–89 mL/min/1.73  m2, < 60 mL/min/1.73  m2), obe-
sity (yes/no), type 2 diabetes (yes/no), hypertension (yes/no), dyslipidemia (yes/no), smoking (non-smoker/
smoker or ex-smoker), and MedDiet score (≤ 10/ > 10-points [P75]); The potential effect modification for eGFR 
by these stratification variables was explored by likelihood-ratio tests comparing the models with and without 
cross-product interaction terms, after adjusting for model 3.
Finally, we performed a sensitivity analysis, in which we repeated the primary analysis but using percentage 
of eGFR change ((1-year eGFR − baseline eGFR)/(baseline eGFR) * 100) instead of eGFR change, adjusting for 
baseline eGFR. Statistical significance was set at p < 0.05.
Ethics approval and consent to participate. The study protocol and procedures were approved accord-
ing to the ethical standards of the Declaration of Helsinki by the Institutional Review Boards (IRBs) of all the 
participating institutions: CEI Provincial de Málaga, CEI de los Hospitales Universitarios Virgen Macarena y 
Virgen del Rocío, CEI de la Universidad de Navarra, CEI de las Illes Balears, CEIC del Hospital Clínic de Bar-
celona, CEIC del Parc de Salut Mar, CEIC del Hospital Universitari Sant Joan de Reus, CEI del Hospital Uni-
versitario San Cecilio, CEIC de la Fundación Jiménez Díaz, CEIC Euskadi, CEI en Humanos de la Universidad 
de Valencia, CEIC del Hospital Universitario de Gran Canaria Doctor Negrín, CEIC del Hospital Universitario 
de Bellvitge, CEIC de IMDEA Alimentación, CEIC del Hospital Clínico San Carlos, CEI Provincial de Málaga, 
CCEIBA de la Investigación Biomédica de Andalucía, CEIC del Hospital General Universitario de Elche, Comité 
de Ética del Hospital Universitario Reina Sofía and CEIC de León. All participants provided informed written 
consent.
Results
At baseline, the mean age of participants was 65 years, the mean BMI 32.5 kg/m2, and 48% were women. The 
mean baseline eGFR was 84.2 mL/min/1.73  m2 and mean change at 1 year was − 0.96 mL/min/1.73  m2. Mean 
daily consumption of caffeinated coffee, decaffeinated coffee, and tea were 42 mL/day (0.8 cup/day), 36 mL/day 
(0.7 cup/day), and 11 mL/day (0.2 cup/day) respectively. The mean intake of caffeine was 24.8 ± 25.7 mg/day. 
Table 1 shows baseline characteristics of study population by categories of coffee and tea consumption. Overall, 
91.7% of participants were daily coffee consumers, and 36.4% drank > 2 cups of coffee/day. In contrast, only 32.5% 
were tea consumers and 11.3% drank at least 1 cup of tea/day. Compared with participants who consumed coffee 
less than daily (< 1 cup/day), those who consumed > 2 cups/day were more likely to be men, whereas tea consum-
ers were more frequently women. Individuals who drank > 2 cups/day of coffee were younger and had higher BMI 
and baseline eGFR. They were more likely to have obesity, diabetes, and dyslipidemia and more frequently used 
oral hypoglycemic drugs, smoked, had higher waist circumference, fasting glucose and educational levels, and 
lower MedDiet adherence. For tea consumption, the associations were mostly in the opposite direction, except 
for education. High coffee consumption was also associated with a high intake of saturated fat, protein, sodium, 
magnesium, and potassium and with low fiber intake. Similar trends were observed for tea, except for saturated 
fat, fiber and alcohol intake, which showed an opposite pattern.
Total coffee consumption was not significantly associated with eGFR changes: β: − 0.51; 95% CI − 1.17, 
0.14 mL/min/1.73  m2 for > 2 cups/day compared with none to < 1 cup/day (p-trend = 0.07) in the fully adjusted 
model 3 (Table 2). Regarding coffee subtypes, caffeinated coffee consumption was associated with a 1-year eGFR 
decline in the model adjusted for age, sex, and baseline eGFR, with a significant β value of − 1.00 (95% CI − 1.52, 
− 0.45) mL/min/1.73  m2 for participants drinking > 2 cups/day compared with those in the lowest category 
(p-trend = 0.001). This association was not substantially affected after adjustment for other potential confound-
ers in model 3, with an eGFR change of − 0.88 (95% CI − 1.52, − 0.23) mL/min/1.73  m2 lower in participants 
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Coffee consumption, cups/day Tea consumption, cups/day
0 to < 1cup/day 1–2 cups/day > 2 cups/day 0 cup/day < 1cup/day ≥ 1 cups/day
n = 1091 n = 2631 n = 2129 n = 3948 n = 1243 n = 660
Caffeinated coffee, mL/day 5.4 ± 11.3 28.4 ± 24.8 76.9 ± 71.5 42.4 ± 55.7 43.1 ± 52.2 35.1 ± 47.6
Decaffeinated coffee, mL/day 6.3 ± 10.3 28.6 ± 24.4 59.6 ± 66.5 37.5 ± 48.9 32.8 ± 45.8 30.4 ± 44.3
Tea, mL/day 16.5 ± 40.1 10.7 ± 25.9 9.3 ± 26.0 0.0 12.8 ± 10.5 75.9 ± 49.3
Caffeine, mg/day 11.5 ± 17.9 18.9 ± 15.7 38.9 ± 31.3 23.9 ± 25.9 25.2 ± 24.5 28.8 ± 23.8
Age, years 65.4 ± 4.9 65.3 ± 4.7 64.4 ± 5.0 65.1 ± 4.9 64.8 ± 4.7 64.9 ± 4.7
Women, % 47.8 52.9 41.8 42.9 56.9 60.9
BMI, kg/m2 32.3 ± 3.5 32.5 ± 3.4 32.7 ± 3.4 32.5 ± 3.4 32.5 ± 3.4 32.4 ± 3.4
Waist circumference, cm 106.7 ± 9.7 107.0 ± 0.2 108.6 ± 9.4 107.9 ± 9.6 106.9 ± 9.5 106.3 ± 10.1
Systolic blood pressure, mmHg 140.7 ± 17.7 139.1 ± 17.0 139.3 ± 16.3 140.2 ± 17.1 138.3 ± 16.5 137.2 ± 16.2
Diastolic blood pressure, mmHg 81.4 ± 10.1 80.6 ± 9.9 80.8 ± 9.7 81.1 ± 9.9 80.4 ± 9.6 79.8 ± 9.4
Plasma fasting glucose, mg/dL 111.9 ± 27.3 112.5 ± 27.9 115.4 ± 30.8 114.2 ± 29.8 111.9 ± 27.6 110.9 ± 25.9
Plasma HD-c, mg/dL 47.6 ± 11.8 48.8 ± 11.8 47.4 ± 11.7 47.5 ± 11.6 48.6 ± 11.4 50.3 ± 13.3
Plasma triglycerides, mg/dL 149.6 ± 75.6 150.7 ± 74.4 152.8 ± 78.0 151.7 ± 75.3 151.3 ± 79.3 148.6 ± 73.7
eGFR, mL/min/1.73  m2 83.8 ± 14.5 83.5 ± 13.9 85.19 ± 13.7 84.1 ± 14.1 84.5 ± 13.4 84.3 ± 14.5
Comorbidities, %
 Obesity (BMI ≥ 30 kg/m2) 69.9 72.1 75.9 73.5 73.4 72.6
 Central obesity 94.0 96.4 96.7* 95.7 96.8 96.2
 Type 2  diabetesa 27.3 30.1 32.8 31.7 30.2 24.7
 Hypercholesterolemia 66.5 69.3 71.0 68.4 69.1 70.9
 Hypertension 82.2 84.3 83.2 84.9 81.7 78.6
 Low HDL-c 45.2 42.0 42.6 42.3 43.6 43.9
 Hypertriglyceridemia 55.4 55.9 54.8 55.8 54.1 55.8
 Hyperglycemia 75.7 74.2 76.7 75.8 75.2 73.3
 CKD (eGFR < 60 mL/min/1.73  m2) 7.8 6.4 6.3 6.8 5.7 7.3
Medication use, %
 Lipid-lowering drugs 48.7 50.8 52.4 51.1 51.9 48.5
 Oral blood glucose-lowering drugs 22.7 26.2 27.9 27.3 26.2 19.2
 Insulin treatment 3.7 4.3 4.5 4.4 3.9 3.9
 Antihypertensive drugs 77.6 78.2 78.1 79.2 76.3 74.8
 ARBs 39.3 36.3 38.6 38.6 36.4 34.9
 ACEis 31.6 31.9 30.9 32.3 29.5 30.6
Education level, %
 Primary education 48.6 52.2 46.1 51.3 45.4 44.7
 Secondary education 30.9 28.2 29.4 29.1 29.6 28.5
 Academic or graduate 20.4 19.6 24.5 18.6 25.0 26.8
Smoking status, % (n)
 Never smoked 49.5 48.5 36.4 42.7 48.9 45.1
 Former smoker 41.5 41.0 46.4 43.6 40.5 44.7
 Current smoker 9.0 10.5 17.1 13.7 10.5 10.1
Leisure time physical activity, METS. min. /
week 375.8 ± 332.1 364.2 ± 338.6 350.6 ± 334.1 361.7 ± 347.5 356.6 ± 306.1 368.6 ± 317.9
MedDiet score (17-points) 8.9 ± 2.6 8.5 ± 2.7 8.2 ± 2.6 8.3 ± 2.6 8.6 ± 2.7 9.1 ± 2.7
Nutrient intake/day
 Energy, kcal 2310 ± 556 2325 ± 525 2455 ± 564 2377 ± 546 2363 ± 554 2339 ± 558
 Saturated fat, g 26.0 ± 5.2 26.1 ± 5.1 26.7 ± 5.9 26.2 ± 5.2 26.8 ± 5.6 26.0 ± 5.9
 Total protein, g 95.5 ± 14.1 97.5 ± 14.2 98.9 ± 15.5 96.8 ± 14.8 99.1 ± 14.2 99.7 ± 14.7
 Fiber, g 26.9 ± 7.8 26.7 ± 7.9 25.0 ± 7.9 24.4 ± 7.8 27.0 ± 7.7 28.9 ± 8.4
 Sodium, mg 2391 ± 509 2441 ± 530 2438 ± 542 2428 ± 544 2434 ± 498 2434 ± 515
 Magnesium, mg 410.2 ± 75.8 421.3 ± 79.2 424.5 ± 84.4 413.3 ± 79.4 429.3 ± 78.1 446.3 ± 86.1
 Potassium, mg 4245 ± 829 4481 ± 840 4537 ± 898 4408 ± 850 4561 ± 832 4724 ± 931
 Alcohol, g 10.8 ± 14.2 11.0 ± 3.5 11.6 ± 15.1 12.2 ± 15.3 8.9 ± 11.4 9.3 ± 11.8
Table 1.  General characteristics of the studied population according to categories of total coffee and tea 
consumption. Values are means (± SD) and percentages for continuous and categorical variables, respectively. 
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL-c high-density 
lipoprotein-cholesterol, ARBs angiotensin-type 2 receptor blockers, ACEis angiotensin converting enzyme 
inhibitors, eGFR estimated glomerular filtration rate, MedDiet Mediterranean diet. a Current diabetes 
was defined as previous diagnosis of diabetes, glycated haemoglobin (HbA1c) ≥ 6.5%, use of antidiabetic 
medication, or having fasting glucose > 126 mg/dL in both the screening visit and baseline visit. b P value for 
comparisons between categories of coffee consumption was tested by ANOVA or  chi2, as appropriated. The 
standard serving size of 1 cup was defined as 50 mL in the questionnaire.
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drinking > 2 cups/day compared to those with none to < 1 cup/day (p-trend = 0.008). When caffeinated coffee was 
analyzed as continuous, eGFR decreased by − 0.17 (95% CI − 0.40, 0.05) mL/min/1.73  m2 per 1 cup/day incre-
ment in the fully adjusted model, however, this result was not significant (p = 0.15). Conversely, the frequency 
of decaffeinated coffee consumption was not associated with changes in eGFR (Table 2).
Concerning tea, the age-, sex, and baseline eGFR-adjusted revealed a non-significant higher decrease in 
eGFR, with β: − 0.61; 95% CI − 1.33, 0.11 mL/min/1.73  m2) in participants drinking ≥ 1cup tea/day compared 
to non-drinkers (p-trend = 0.10). This association was strengthened after adjustment for confounders (model 
3), resulting in a significant β of − 0.93 (95% CI − 1.67, − 0.18) mL/min/1.73  m2 1-year decrease in eGFR for 
participants drinking ≥ 1cup/day compared with non-drinkers (p-trend = 0.02). Similarly, for each 1 cup/day 
increase in tea consumption a decrease of − 0.55 (95% CI − 0.93, − 0.16) mL/min/1.73  m2 in eGFR (model 3) 
was observed (Table 2).
Similar results were observed when all of these analyses were repeated using percentage of change of eGFR 
instead of eGFR change, adjusting for baseline eGFR values (data not shown). Overall, we found no evidence 
that the observed associations varied across subgroups of sex, age, eGFR, obesity, diabetes, hypertension, dyslipi-
demia, smoking, MedDiet score at baseline, and intervention group (Fig. 1 and Supplementary Fig. S1 online).
In multivariable logistic regression models, the caffeinated coffee consumption remained significantly associ-
ated with an increased risk of a rapid eGFR decline > 3 mL/min/1.73  m2 when comparing > 2 versus none to < 1 
cups/day (full adjusted OR, 1.19; 95% CI 1.01–1.41) (Table 3).
Compared to participants in the lowest tertile of caffeine intake, in the fully adjusted model, those in the 
top tertile showed a significantly higher eGFR decline, with a mean difference of − 0.94 (95% CI − 1.51, − 0.38) 
mL/min/1.73  m2 (p-trend = 0.001) (Table 4). For each additional 50 mg/day of caffeine intake, eGFR decreased 
by − 0.60 (95% CI − 1.04, − 0.17) mL/min/1.73  m2 (model 3). When analyzed as estimated caffeine intake from 
coffee and tea, a similar pattern of eGFR decline was observed (Table 4). No significant association between caf-
feine intake from soft drinks and kidney function was observed, (tertile 3 vs. tertile 1, β: − 0.23; 95% CI − 0.82, 
0.37; p-trend = 0.47).
Discussion
In this study, we examined the association between coffee, tea, and caffeine intake and 1-year changes in eGFR 
in older Mediterranean individuals with overweight/obesity and MetS. We found no association between total 
coffee consumption and eGFR changes. However, when we explored the association by coffee subtypes, individu-
als who consumed > 2 cups/day of caffeinated coffee disclosed a greater eGFR decline and higher risk of rapid 
kidney function decline compared to those who consumed none to < 1 cup/day. Similar results were observed 
for drinkers of one or more cups of tea/day compared to non-consumers. Besides, participants in the highest 
tertile of total dietary caffeine intake showed a higher decline in eGFR than those in the reference tertile. No 
association of decaffeinated coffee consumption with eGFR changes was observed.
Coffee is a seed that contains a complex matrix of vitamins, minerals, bioactive phytochemicals, caffeine, 
diterpenes, melanoidins, and trigonelline with potential beneficial effects on human  health8,10,36. Therefore, the 
association of coffee with health outcomes, especially non-communicable chronic diseases such as CKD has 
been of research interest in the last  decade10,11.
Unlike our results, epidemiological studies suggest that regular coffee consumption is either unassociated with 
kidney  function6,7,20 or has a protective effects against CKD in healthy middle-aged  adults21,24. Cross-sectionally, 
the association between coffee and kidney function has been mainly explored in Asian populations. In two 
studies conducted in healthy Japanese  adults14,15, higher eGFR was observed in usual coffee drinkers (≥ 1 cups/
day) compared to non-drinkers. Similarly, in Korean  women18, habitual coffee consumption (≥ 2 cups/day) was 
associated with a lower risk of CKD only in diabetic women. However, other studies in Japanese middle-aged 
adults reported no association between coffee and  eGFR16,17. Notwithstanding, higher cross-sectional eGFRs 
values do not necessarily reflect better kidney function; therefore, these results should be taken with caution 
since certain kidney diseases may also manifest hyperfiltration in early  stages37. Finally, the results of a recent 
meta-analysis of cross-sectional studies conducted by Wijarnpreecha et al.7 reported no significant association 
between coffee consumption and CKD risk in males, and a trend to a lower risk of CKD in women. Contrary, 
in our study, the associations between caffeinated coffee or tea consumption and eGFR were most apparently 
among men, despite interactions were not significant. Further research is warranted to clarify the differences 
observed by sex, and if they are proven to understand the plausible mechanisms involved.
Recently, prospective studies have reported inconsistent results. Three studies, one conducted in US  adults21 
and two in Asian  populations19,24, reported a decreased risk of incident CKD in healthy individuals with greater 
coffee consumption. In contrast, a study conducted in an Iranian population revealed no association between 
coffee and CKD incidence after 6 years of follow-up22. The only epidemiological study conducted in an European 
population reported a cross-sectional positive association between coffee consumption and eGFR at baseline, but 
no prospective association with eGFR changes after 15 year follow-up20. Until now, the only RCT in 19 young 
Japanese revealed a beneficial effect of coffee consumption for 2 weeks, but not green tea, on cystatin-C-based 
 eGFR23.
The main discrepancies between previous studies and our observations might be attributable to the popu-
lations examined, follow-up time, and the assessment tools used. Most studies were conducted in apparently 
healthy middle-aged populations, and none of them included overweight/obese older adults at high cardiovas-
cular risk. Additionally, previous studies have focused on exploring the association between total coffee and 
kidney function, but none of them have explored differences by coffee subtypes. Further, we also determined 
whether the observed detrimental effects of caffeinated coffee and tea consumption on kidney function differed 
7
Vol.:(0123456789)
Scientific Reports |         (2021) 11:8719  | https://doi.org/10.1038/s41598-021-88028-7
www.nature.com/scientificreports/
across subgroups according to various baseline factors and similar trends were seen; this type of analysis was 
seldom performed in previous studies.
The association between tea and kidney dysfunction has been less explored and the few studies in the field had 
reported no significant  associations15,19,20,22. We observed that the consumption of ≥ 1cup tea/day was associated 
with higher eGFR decline. Despite, in our study tea consumption was lower than caffeinated coffee consump-
tion, our findings regarding caffeine intake suggest that this nutrient could be the causal for the deleterious renal 
effect observed.
Additionally, we found no association between decaffeinated coffee and kidney function, that might rein-
force the potentially harmful effect of  caffeine13. However, the mechanism that confers this negative effect of 
Table 2.  Crude and multivariate linear regression models of 1-year changes in eGFR according to categories of 
coffee and tea consumption at baseline. Values are means (95% CI) unless otherwise indicated. eGFR estimated 
glomerular filtration rate, Ref. referent value. P value for trend based on multivariate linear regression treating 
the median values of each category as an ordinal variable. Model 1: adjusted for sex (men or women), age 
(years, continuous), and baseline eGFR (mL/min/1.73  m2, continuous). Model 2: additionally adjusted for 
BMI (kg/m2, continuous), smoking (never, current, or former smoker), educational level (primary, secondary 
education or academic/graduate), physical activity (MET-min/day, continuous), type 2 diabetes prevalence 
(yes or no), dyslipidemia (yes or no), hypertension (yes or no), center (four categories by number of recruited 
participants: < 200, 200–250, 250–300, or ≥ 300), intervention group (intervention or control group), MedDiet 
score (17-points, continuous) and total energy intake (kcal/day, quartiles). Model 3: additional adjusted for 
dietary intakes of total protein, saturated fat, alcohol, fiber, sodium, magnesium, potassium (each categorized 
by energy-adjusted quartiles), 1-year changes in systolic blood pressure (mm Hg, continuous) and 1-year 
changes body weight (kg, continuous). Model 3 was further adjusted (cup/day, continuous) for coffee (for tea 
analysis), tea (for each coffee analysis), caffeinated coffee (for decaffeinated coffee analysis), or decaffeinated 
coffee (for caffeinated coffee analysis). All analyses were conducted with robust estimates of the variance 
to correct for intra-cluster correlation. a P < 0.05 (compared to the reference group). b P < 0.05. The standard 
serving size of 1 cup was defined as 50 mL in the questionnaire.
Coffee consumption, cups/day
P for trend Per cup/day increase0 to < 1cup/day 1–2 cups/day > 2 cups/day
Total coffee, n (fre-
quency) 1091 2631 2129
eGFR change, mL/
min/1.73  m2 − 0.75 (− 0.32, − 0.19) − 0.73 (− 1.09, − 0.37) − 1.36 (− 1.73, − 0.99)
 versus 0 to < 1cup/day
  Model 1 Ref − 0.08 (− 0.70, 0.55) − 0.52 (− 1.15, 0.11) 0.05 − 0.09 (− 0.29, 0.10)
  Model 2 Ref 0.05 (− 0.57, 0.68) − 0.31 (− 0.95, 0.32) 0.18 − 0.03 (− 0.22, 0.17)
  Model 3 Ref − 0.11 (− 0.74, 0.52) − 0.51 (− 1.17, 0.14) 0.07 − 0.05 (− 0.26, 0.15)
Caffeinated coffee, n 
(frequency) 3169 1479 1203
eGFR change, mL/
min/1.73  m2 − 0.78 (− 1.11, − 0.46) − 0.84 (− 1.30, − 0.37) − 1.59 (− 2.07, − 1.10)
 versus 0 to < 1cup/day
  Model 1 Ref − 0.33 (− 0.86, 0.21) − 1.00 (− 1.56, − 0.45)a 0.001 − 0.26 (− 0.45, − 0.07)b
  Model 2 Ref − 0.30 (− 0.83, 0.23) − 0.93 (− 1.49, − 0.37)a 0.001 − 0.23 (− 0.42, − 0.03)b
  Model 3 Ref − 0.23 (− 0.81, 0.36) − 0.88 (− 1.52, − 0.23)a 0.008 − 0.17 (− 0.40, 0.05)
Decaffeinated coffee, n 
(frequency) 3381 1522 948
eGFR change, mL/
min/1.73  m2 − 1.04 (− 1.34, − 0.74) − 0.70 (− 1.18, − 0.22) − 1.10 (− 1.65, − 0.54)
 versus 0 to < 1cup/day
  Model 1 Ref 0.48 (− 0.05, 1.02) 0.40 (− 0.20, 1.02) 0.11 0.21 (− 0.01, 0.43)
  Model 2 Ref 0.52 (− 0.02, 1.05) 0.53 (− 0.07, 1.13) 0.05 0.24 (− 0.02, 0.47)
  Model 3 Ref 0.33 (− 0.27, 0.94) 0.36 (− 0.39, 1.10) 0.31 0.19 (− 0.09, 0.47)
Tea consumption, cups/day
P for trend Per cup/day increase0 cup/day < 1cup/day ≥ 1 cups/day
Tea, n (frequency) 3948 1243 660
eGFR change, mL/
min/1.73  m2 − 0.85 (− 1.13, − 0.55) − 1.07 (− 1.57, − 0.58) − 1.44 (− 2.13, − 0.74)
 versus 0 cup/day
  Model 1 Ref − 0.19 (− 0.73, 0.36) − 0.61 (− 1.33, 0.11) 0.10 − 0.38 (− 0.75, − 0.01)b
  Model 2 Ref − 0.31 (− 0.85, 0.24) − 0.89 (− 1.62, − 0.16)a 0.02 − 0.54 (− 0.92, − 0.17)b
  Model 3 Ref − 0.29 (− 0.84, 0.26) − 0.93 (− 1.67, − 0.18)a 0.02 − 0.55 (− 0.93, − 0.16)b
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Figure 1.  Mean multivariable-adjusted differences (95% CI) for 1-year changes in eGFR between the two highest and the 
lowest categories of caffeinated coffee consumption at baseline stratified by group. eGFR, estimated glomerular filtration 
rate; MedDiet, Mediterranean diet. Model adjusted (except the stratification factor itself) for sex (men or women), age 
(years, continuous), baseline eGFR (mL/min/1.73  m2, continuous), BMI (kg/m2, continuous), smoking (never, current, or 
former smoker), educational level (primary, secondary education or academic/graduate), physical activity (MET-min/day, 
continuous), type 2 diabetes prevalence (yes or no), dyslipidemia (yes or no), hypertension (yes or no), center (four categories 
by number of recruited participants: < 200, 200–250, 250–300, or ≥ 300), intervention group (intervention or control group), 
MedDiet score (17-points, continuous), total energy intake (kcal/day, quartiles), dietary intakes of total protein, saturated 
fat, alcohol, fiber, sodium, magnesium, potassium (each categorized at energy-adjusted quartiles), 1-year changes in systolic 
blood pressure (mmHg, continuous), and 1-year changes in body weight (kg, continuous), decaffeinated coffee, and tea 
consumption (cup/day, continuous). All analyses were conducted with robust estimates of the variance to correct for intra-
cluster correlation. aP < 0.05 (compared to the reference group). The standard serving size of 1 cup was defined as 50 mL in the 
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caffeine intake is  uncertain36. A possible explanation could be related with the structural similarity of caffeine and 
adenosine acting as a nonselective antagonist of A1 adenosine receptors, which may be a potential mechanism 
for the impairment of renal  function11. On distal afferent arterioles, A1 adenosine receptor activation causes 
vasoconstriction and decreases  eGFR38. By contrast, adenosine antagonism by caffeine may prevent afferent arte-
riolar constriction or induce vasodilation, increasing renal plasma flow and acute elevation of  eGFR11. Probably 
this increase in eGFR could lead to acute compensatory hyperfiltration and subsequent accelerated decline in 
 GFR37. This hypothesis may be partly supported by the observed relationship in our study between caffeinated 
coffee and a slightly higher baseline eGFR and, subsequently, a higher 1-year eGFR decline. In this context, it 
has been reported that, compared to decaffeinated coffee, caffeinated coffee could cause a short-lasting increase 
in blood pressure in healthy young  subjects39. Also, in young-to-middle-age hypertensive adults, caffeinated cof-
fee drinking has been linked with glomerular  hyperfiltration40, which may be exaggerated in older individuals 
with pre-existing  comorbidities13 (e.g., hypertension) as our studied population, but warrants further studies. 
In fact, in experimental studies conducted in obese diabetic rats, administration of caffeine for 2 weeks induced 
early renal injury characterized by proteinuria, increased renal vascular resistance, and increased heart  rate41. 
Moreover, the same authors reported that long-term caffeine consumption exacerbated renal failure and induced 
more severe tubule-interstitial and glomerular  damage42. Nevertheless, this has not been explored in humans 
and RCTs are needed.
Our study has some strengths. First, the relatively large sample size, its prospective design, and adjustment for 
many potential confounding factors. Secondly, we examined the association between eGFR and coffee subtypes, 
Table 3.  Odds ratio (95% confidence intervals) of rapid eGFR decline (1-year changes in eGFR > 3 mL/
min/1.73  m2) according to categories of coffee and tea consumption at baseline. Values are means (95% CI) 
unless otherwise indicated. eGFR estimated glomerular filtration rate, Ref. referent value. P value for trend 
based on multivariate logistic regression treating the median values of each category as an ordinal variable. 
Model 1: adjusted for sex (men or women), age (years, continuous), and baseline eGFR (mL/min/1.73  m2, 
continuous). Model 2: additionally adjusted for BMI (kg/m2, continuous), smoking (never, current, or former 
smoker), educational level (primary, secondary education or academic/graduate), physical activity (MET-min/
day, continuous), type 2 diabetes prevalence (yes or no), dyslipidemia (yes or no), hypertension (yes or no), 
center (four categories by number of recruited participants: < 200, 200–250, 250–300, or ≥ 300), intervention 
group (intervention or control group), MedDiet score (17-points, continuous) and total energy intake (kcal/
day, quartiles). Model 3: additional adjusted for dietary intakes of total protein, saturated fat, alcohol, fiber, 
sodium, magnesium, potassium (each categorized by energy-adjusted quartiles), 1-year changes in systolic 
blood pressure (mm Hg, continuous) and 1-year changes body weight (kg, continuous). Model 3 was further 
adjusted (cup/day, continuous) for coffee (for tea analysis), tea (for each coffee analysis), caffeinated coffee 
(for decaffeinated coffee analysis), or decaffeinated coffee (for caffeinated coffee analysis). All analyses were 
conducted with robust estimates of the variance to correct for intra-cluster correlation. a P < 0.05 (compared to 
the reference group). b P < 0.05. The standard serving size of 1 cup was defined as 50 mL in the questionnaire.
Coffee consumption, cups/day
P for trend Per cup/day increase0 to < 1cup/day 1–2 cups/day > 2 cups/day
Total coffee, n (frequency) 1091 2631 2129
Rapid eGFR decline, cases (%) 362 (33.2) 898 (34.1) 776 (36.5)
 Model 1 1 (Ref.) 1.06 (0.91, 1.23) 1.15 (0.98, 1.35) 0.06 1.02 (0.97, 1.07)
 Model 2 1 (Ref.) 1.03 (0.88, 1.20) 1.09 (0.93, 1.28) 0.24 1.00 (0.95, 1.06)
 Model 3 1 (Ref.) 1.06 (0.90, 1.23) 1.11 (0.94, 1.32) 0.21 1.00 (0.94, 1.05)
Caffeinated coffee, n (frequency) 3169 1479 1203
Rapid eGFR decline, cases (%) 1068 (33.7) 506 (34.2) 462 (38.4)
 Model 1 1 (Ref.) 1.06 (0.93, 1.21) 1.27 (1.10, 1.45)a 0.001 1.06 (1.01, 1.12)
 Model 2 1 (Ref.) 1.05 (0.92, 1.20) 1.24 (1.07, 1.43)a 0.004 1.05 (1.00, 1.11)
 Model 3 1 (Ref.) 1.02 (0.88, 1.18) 1.19 (1.01, 1.41)a 0.04 1.03 (0.97, 1.09)
Decaffeinated coffee, n (frequency) 3381 n1522 948
Rapid eGFR decline, cases (%) 1194 (35.3) 520 (34.2) 322 (33.9)
 Model 1 1 (Ref.) 0.94 (0.82, 1.06) 0.89 (0.77, 1.04) 0.95 0.95 (0.90, 1.01)
 Model 2 1 (Ref.) 0.93 (0.81, 1.06) 0.86 (0.74, 1.01) 0.05 0.94 (0.89, 1.00)
 Model 3 1 (Ref.) 0.96 (0.83, 1.11) 0.87 (0.72, 1.05) 0.14 0.94 (0.87, 1.01)
Tea consumption, cups/day
P for trend Per cup/d increase0 cup/day < 1cup/day ≥ 1 cups/day
Tea, n (frequency) 3948 1243 660
Rapid eGFR decline, cases (%) 1369 (34.7) 424 (34.1) 243 (36.8)
 Model 1 1 (Ref.) 0.97 (0.85, 1.11) 1.10 (0.92, 1.31) 0.30 1.07 (0.97, 1.17)
 Model 2 1 (Ref.) 0.99 (0.87, 1.14) 1.17 (0.97, 1.40) 0.10 1.10 (1.00, 1.21)
 Model 3 1 (Ref.) 0.97 (0.84, 1.12) 1.15 (0.96, 1.39) 0.12 1.10 (1.00, 1.21)
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which gives greater insight into the potential effect of coffee and caffeine on kidney function. Finally, we con-
ducted sub-group analyses to examine whether kidney function decline was accelerated by unhealthy behaviors 
(e.g., smoking or a poor diet) or pre-existing comorbid conditions. Nevertheless, we also acknowledge some 
limitations. It should be underlined that the caffeine content in coffee, tea, and other beverages (e.g., soft drinks) 
and foods varies greatly, which may lead to misclassification, and also that coffee composition can depend on the 
type of coffee bean and the brewing process used, which may influence the biological effects it has on the human 
organism. Also, SCr-based eGFR, a common biomarker of kidney function used in almost all epidemiologic 
studies, may overestimate true GFR values. Finally, our study was conducted in aged Mediterranean individuals 
with MetS, therefore our findings cannot be extrapolated to other populations.
In summary, caffeinated coffee and tea consumption and caffeine intake were associated with a greater 1-year 
decline of renal function in older individuals at high cardiovascular risk. Further studies are needed to clarify 
these associations; if proven, advice on coffee and tea consumption along with caffeine intake should be included 
in nutritional strategies for kidney disease prevention, particularly in individuals at high risk.
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